GLP-1 & Prebiotics: Science, Claims, and Responsible Positioning
The Global Prebiotic Association’s GLP-1 white paper gives brands, formulators, and healthcare professionals the scientific and regulatory foundation to position prebiotic products in the GLP-1 space accurately and compliantly.
GLP-1 Is
Reshaping
Weight Management.
Here's Where Prebiotics Fit.
Glucagon-Like Peptide-1 (GLP-1) receptor agonists fundamentally changed the toolbox for managing weight and metabolic health. Prebiotic brands are now asking how they fit into that picture, and where the lines are.
This white paper provides the scientific rationale behind the Global Prebiotic Association’s stance on how to position prebiotic products responsibly in this space.
The Gut Is Central
to the GLP-1 Story
GLP-1 receptor agonists are now among the most prescribed medications globally. However, up to 90% of users experience gastrointestinal side effects, and most do not meet the recommended fiber intake. Additionally, a growing body of research shows that the gut microbiome directly influences endogenous GLP-1 secretion through short-chain fatty acid (SCFA) production.
This ambiguity is precisely why the Global Prebiotic Association published this white paper, providing the scientific rationale for our previous guidance on the best practices for GLP-1-related claims for prebiotic products.
What Makes This Space So Complex?
The science is real, but complicated
Preclinical studies consistently show that prebiotics stimulate GLP-1 secretion by generating SCFAs in the large intestine. Human evidence is building, but it’s in no way comparable to the effect of a drug. That gap matters for how brands frame claims.
GLP-1 users have documented nutritional gaps
A cross-sectional study of GLP-1 RA users in the US found inadequate intakes of dietary fiber, calcium, iron, magnesium, potassium, and vitamins A, C, D, and E. Reduced food intake and shifts in eating behavior are part of it. Prebiotic and fiber supplementation have a role, but context and framing are everything.
The claim environment is narrow on purpose
Positioning prebiotics as substitutes for, or enhancers of, GLP-1 medications risks pharmaceutical classification. Referencing specific branded medications in prebiotic claims isn’t advisable. Broad, well-supported claims related to gut health and regularity are appropriate, and this paper clarifies why.
What You'll Find in This White Paper:
How gut dysbiosis in obesity relates to reduced GLP-1 response
Safety profile of GLP-1 RA medications and the nutritional gaps they create
Evidence on prebiotic types (FOS, GOS, resistant starch, inulin) and their effects on GLP-1 and satiety markers
Strategies for using prebiotics alongside GLP-1 therapies, including managing GI side effects
Regulatory guidance across major jurisdictions
GPA best practices for GLP-1-related claims
Built for Brands, Formulators, and
Healthcare Professionals
Whether you’re formulating a product for weight management, metabolic health, or building a content strategy around this category, the GPA GLP-1 White Paper gives you the scientific foundation to operate with clarity and credibility.